Prostate Cancer

Significant cost-savings in treating patients with prostate cancer could be achieved in the US healthcare system with the use of the cell-cycle progression (CCP) gene-expression assay called Prolaris. Read More ›

A novel gene panel is showing promise for determining which treatment-naïve patients with prostate cancer could benefit from intensified treatment. Read More ›

In men with prostate cancer undergoing curative radiation therapy, it may be possible to preserve sexual function by using a vessel-sparing radiation technique, according to the 5-year follow-up results from a study of men who underwent vessel-sparing radiation therapy in this setting. Read More ›

Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation. Read More ›

Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting. Read More ›

Prostate cancer screening with prostate-specific antigen (PSA) tests should focus on men aged 55 to 69 years, the group that is the most likely to benefit from screening. Read More ›

Prostate cancer is the most frequently detected cancer in men: 1 of 6 men will be diagnosed with prostate cancer during their lifetime based on Medicare enrollment data. Read More ›

In men, prostate cancer is the most commonly diagnosed solid tumor malignancy in the United States and is the second highest cancer-specific cause of death after lung cancer. Read More ›

Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment. Read More ›

Because it is typically a slow- growing tumor type, patients with prostate cancer tend to be slightly older than patients in other oncology settings. Read More ›

Page 3 of 3

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: